The PRECISE-EGFR study is a prospective, observational project designed to generate patient-derived in vitro models (cell cultures and organoids) from individuals with non-small cell lung cancer (NSCLC) carrying EGFR mutations. These models will be used to evaluate sensitivity to different anti-EGFR therapies and explore mechanisms of drug resistance. Using residual biological samples collected during routine clinical practice, the study will not interfere with patient care. Researchers will also compare the molecular characteristics of the models with the original tumors to ensure reliability. The overall aim is to improve precision oncology approaches, identifying the most effective treatments for specific EGFR mutation subtypes while minimizing toxicity and resistance.
Study Type
OBSERVATIONAL
Enrollment
30
Generate in vitro cellular models derived from tumors of patients with NSCLC carrying EGFR mutations, using residual biological samples, to be used for evaluating sensitivity to anti-EGFR drugs.
The primary objective is to generate in vitro cellular models derived from tumors of patients with non-small cell lung cancer (NSCLC) harboring EGFR mutations, using residual biological samples, to be used for evaluating sensitivity to anti-EGFR drugs.
Time frame: Throughout the study, 3 years
Degree of molecular concordance between the original tumor and derived models
Compare the molecular characteristics of the obtained models with those of the original tumor in order to verify their biological concordance.
Time frame: Throughout the study, 3 years
Variation in cell viability in in vitro models following treatment with anti-EGFR drugs
To explore, in an exploratory manner, the in vitro response to anti-EGFR drugs in relation to the type of EGFR mutation.
Time frame: Throughout the study, 3 years
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.